Pyxis Oncology (PYXS) filed a shelf registration statement with the US Securities and Exchange Commission on Wednesday for the potential sale of up to $350 million in securities, to be offered from time to time.

The filing covers common stock, preferred stock, warrants, debt securities, units, and rights to purchase common stock, preferred stock, debt securities or units.

Pyxis said it intends to use the net proceeds for general corporate purposes, including working capital, operating expenses and capital expenditures, as well as to acquire or invest in businesses and products that are complementary to the company.